Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Gao Y, Söderdahl G, Österborg A, Smith CIE, Vesterbacka J, Wullimann D, Cuapio A, Akber M, Bogdanovic G, Muschiol S, Åberg M, Loré K, Chen MS, Ljungman P, Buggert M, Aleman S, Ljunggren HG

Open source

DOI: 10.1016/j.ebiom.2026.106279
Published: 2026 Jun
Container: EBioMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ebiom.2026.106279,
  title = {Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.},
  author = {Chen P and Bergman P and Blennow O and Hansson L and Mielke S and Nowak P and Gao Y and Söderdahl G and Österborg A and Smith CIE and Vesterbacka J and Wullimann D and Cuapio A and Akber M and Bogdanovic G and Muschiol S and Åberg M and Loré K and Chen MS and Ljungman P and Buggert M and Aleman S and Ljunggren HG},
  year = {2026},
  journal = {EBioMedicine},
  doi = {10.1016/j.ebiom.2026.106279},
  url = {https://doi.org/10.1016/j.ebiom.2026.106279}
}

RIS

TY  - JOUR
TI  - Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.
AU  - Chen P
AU  - Bergman P
AU  - Blennow O
AU  - Hansson L
AU  - Mielke S
AU  - Nowak P
AU  - Gao Y
AU  - Söderdahl G
AU  - Österborg A
AU  - Smith CIE
AU  - Vesterbacka J
AU  - Wullimann D
AU  - Cuapio A
AU  - Akber M
AU  - Bogdanovic G
AU  - Muschiol S
AU  - Åberg M
AU  - Loré K
AU  - Chen MS
AU  - Ljungman P
AU  - Buggert M
AU  - Aleman S
AU  - Ljunggren HG
PY  - 2026
JO  - EBioMedicine
DO  - 10.1016/j.ebiom.2026.106279
UR  - https://doi.org/10.1016/j.ebiom.2026.106279
ER  -

APA

P, C., P, B., O, B., L, H., S, M., P, N., Y, G., G, S., A, Ö., CIE, S., J, V., D, W., A, C., M, A., G, B., S, M., M, Å., K, L., MS, C., P, L., M, B., S, A., & HG, L. (2026). Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.. EBioMedicine. https://doi.org/10.1016/j.ebiom.2026.106279

Source records

pubmed · retrieved 2026-09-25T14:59:30.853Z
europe-pmc · retrieved 2026-09-25T14:59:30.873Z